Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria
Launched by MENZIES SCHOOL OF HEALTH RESEARCH · Feb 14, 2017
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
Plasmodium knowlesi is the most common cause of malaria, and malaria deaths, in Sabah, Malaysia. Acute kidney injury (AKI) is a common feature of severe knowlesi malaria; however the mechanisms of AKI in knowlesi malaria are unknown. In falciparum malaria, recent evidence suggests that oxidative stress from haemolysis-related cell-free haemoglobin (CFHb) may contribute to pathogenesis of AKI.
Cell-free haemoglobin and oxidative stress: CFHb is released during intravascular haemolysis, and when exceeding the binding capacity of plasma haptoglobin, is filtered by the glomeruli and enters the...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient age ≥ 5 years
- • 2. Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi.
- • 3. Temperature \>38C on admission or fever during the preceding 48 hours
- • 4. Enrolled within 18 hours of commencing antimalarial treatment
- • 5. Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Malay and copies provided to the patient.
- Exclusion Criteria:
- • 1. Patient or relatives unable or unwilling to give informed consent
- • 2. Contraindication or allergy to paracetamol or artesunate therapy
- • 3. Known cirrhosis, or \>6 standard alcoholic drinks/day
- • 4. Pregnancy
About Menzies School Of Health Research
The Menzies School of Health Research is a leading research institution dedicated to improving health outcomes through innovative research and education. Based in Australia, Menzies focuses on key areas such as infectious diseases, chronic conditions, and Indigenous health, leveraging interdisciplinary approaches to address complex health challenges. With a commitment to translating research findings into practical applications, Menzies collaborates with local communities, health organizations, and policymakers to enhance healthcare delivery and promote health equity. Through its robust clinical trial programs, Menzies aims to advance scientific knowledge and contribute to evidence-based practices that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kota Kinabalu, Sabah, Malaysia
Keningau, Sabah, Malaysia
Kota Marudu, Sabah, Malaysia
Ranau, Sabah, Malaysia
Patients applied
Trial Officials
Giri M Rajahram, MD
Principal Investigator
Clinical Research Center, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
Bridget Barber, MBBS
Study Director
Menzies School of Health Research
Nicholas Anstey, PhD
Study Director
Menzies School of Health Research
Matthew Grigg, MBBS
Study Director
Menzies School of Health Research
Timothy William, MBBS
Study Director
Jesselton Medical Centre
Jayaram Menon, MBBS
Study Director
Ministry of Health, Malaysia
Tsin Yeo, MBBS
Study Director
Menzies School of Health Research
Katherine Plewes, MD
Study Director
Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand
Arjen Dondorp, MD
Study Director
Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand
Daniel Cooper, MBChB
Study Director
Menzies School of Health Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials